Comparison of Anti–Programmed Cell Death Ligand 1 Therapy Combinations vs Sunitinib for Metastatic Renal Cell Carcinoma: A Meta-analysis

This meta-analysis of 3 randomized clinical trials evaluates the association of combined anti–PD-L1 agents with survival and response rate among patients with metastatic renal cell carcinoma.

Detalles Bibliográficos
Autores principales: Maiorano, Brigida Anna, Ciardiello, Davide, Maiello, Evaristo, Roviello, Giandomenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196874/
https://www.ncbi.nlm.nih.gov/pubmed/37200035
http://dx.doi.org/10.1001/jamanetworkopen.2023.14144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196874/
https://www.ncbi.nlm.nih.gov/pubmed/37200035
http://dx.doi.org/10.1001/jamanetworkopen.2023.14144

Ejemplares similares